European Medicines Agency recommends restricting GlaxoSmithKline’s Pandemrix | FirstWord Pharma | Veille Pharma |
The European Medicines Agency on Thursday called for the label of GlaxoSmithKline’s influenza A (H1N1) vaccine Pandemrix to be updated to restrict use in individuals under age 20 when other seasonal trivalent influenza vaccines are available and only if immunisation against influenza A H1N1 is still needed. However, the agency noted that the overall benefit-risk profile of the vaccine remains positive.